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BACKGROUND: The liver is vulnerable to injury from the first 
line anti-tuberculosis drugs. This may result in mortality, long term 
morbidity and reduced compliance to therapy. Nigeria recently 
introduced fixed drug combinations in the treatment of children 
amid concerns of hepatotoxicity. A 6-year-old boy was treated in 
our unit had fulminant hepatic failure two weeks after completing 
his anti-tuberculosis therapy. This prompted the unit to investigate 
hepatotoxicity due to anti-tuberculosis therapy among children. 
There is no data on the incidence of hepatotoxicity due to 
antituberculosis therapy among Nigerian children, and no uniform 
guide to monitoring of patients exists. The objective of this study 
was to investigate the incidence of hepatotoxicity among children 
receiving anti-tuberculosis therapy. 
METHODS: A cross-sectional study was conducted among all 62 
cases that completed treatment over a two year period. Liver 
Function Tests was done at baseline and 2 and 5 months of 
therapy. Elevation of Alanine aminotransferase and/or Aspartate 
aminotransferase above 3 times the reference values was 
considered an indication of hepatotoxicity.  
RESULTS:  A total of 62 patients aged 3 months -17 years were 
treated at our unit during the study period. Twenty-two (35.5%) 
had elevated liver enzymes at baseline. Four (6.5%) had elevation 
of alanine aminotransferase of 3 times the upper limit at 2 months, 
but at 5 months, tests were within normal limits in all patients. 
Hepatotoxicity defined as liver enzymes above 3 times upper limit 
was not documented among the 62 cases treated over the period.  
CONCLUSION: Hepatotoxicity due to antituberculosis therapy is 
uncommon in children, hence repeated routine evaluation of liver 
function may not be necessary in all patients receiving anti-TB 
therapy.  
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Tuberculosis (TB) remains a global public health 
threat, but Nigeria contributes disproportionately 
to the global disease burden and is the 3
rd
 high 
burden disease country with a prevalence of 
326/100,000 in 2013 (1). Globally and in Nigeria, 
childhood TB accounts for about 6% of all new 
cases (2). In Nigeria, 5,463 cases were notified in 
2014 mostly among those 5-14 years of age (3). 
TB is preventable and treatable in all age groups 
including in children. The treatment of all cases of 
TB is central to the care and control of TB in all 
settings. Antituberculosis drugs (ATD) became 
available in the 20
th
 century. The long duration of 
therapy has always been a major drawback in 
successful control of the disease (4). In addition, 
adverse drug reaction greatly influences adherence 
and compliance to antituberculosis therapy (ATT). 
Hepatotoxicity arising from the use of 
antituberculosis has remained a source of concern 
to medical practitioners (5). This is because the 
drugs-Isoniazid (H), Rifampicin (R) and 
Pyrazinamide (Z)-usually implicated in hepatic 
toxicity are key components of ATT (5). The use 
of the fixed dose combination (FDC) in children 
was also accompanied with worries of probable 
increase in cases of hepatic toxicity
 
(5,6). 
Incidence of drug-induced hepatotoxicity in 
childhood is between 3% and 10%, and severe 
hepatotoxicity is documented to be below 1% in 
children (5-8). The patients who have 
hepatotoxicity from ATT can have variable 
presentation from asymptomatic to acute liver 
failure and fulminant disease
 
(5).There is no 
uniform recommendation for monitoring 
paediatric patients on ATT for hepatotoxicity 
(6,7). Furthermore, there is no published study on 
ATT hepatotoxicity in paediatric patients in 
Nigeria. A 5-year-old male patient of our unit 
developed acute fulminant hepatitis shortly after 
completing a 6-month course of ATT. The patient 
was however never documented to have developed 
hepatotoxicity due to ATT, because patients were 
not routinely monitored during therapy. Thus, 
many unanswered questions arose. Therefore, over 
a two year period in our centre, clinical data of all 
children diagnosed with TB was prospectively 
collected using a study protocol.  Data on socio-
demographic distribution, clinical features, 
previous treatment for TB, investigations and 
results, and treatment and adverse events was 
systematically collected. The aim of the study was 
to investigate the occurrence of hepatotoxicity 
among the patients during treatment. This study 
was conducted with the utmost ethical 
consideration as contained in the principles of the 
Helsinki Declaration. This paper reports our 
finding on hepatotoxicity among paediatric 
patients treated with ATT.   
 




, 2014 and December 31
st
, 
2015 data was prospectively collected on socio-
demographics (social class was assigned based on 
Oyedeji classification), clinical features, 
diagnosis, co-morbidities and nutritional status. 
All patients were screened for HIV.  All patients 
in the two year period received the fixed-dose 
combination (FDC) and were treated following the 
treatment guidelines of the National Tuberculosis 
and Leprosy Control Programme (NTLCP) in 
Nigeria. Pulmonary TB and other extrapulmonary 
forms except meningitis and osteoarthicular 
disease received treatment for 6 months (2RHZ 
+E)/ 4(RH). The continuation phase was 
prolonged to 10 months for meningitis and 
osteoarticular diseases. Drug dosages for FDC 
were R 10-20mg/kg; H 7-15mg/kg; Z 30-
40mg/kg. Before the commencement of anti-
tuberculosis therapy (ATT), at 2 months and 5 
months, patients had liver function tests (LFT) 
consisting of Alanine aminotransferase ALT,  
Aspartate aminotransferase (AST), Alkaline 
Phosphatase (ALK (P) and serum bilirubin. ALT 
and AST rise of more than 3 fold of the normal 
was considered significant. Patients with any 
elevation of liver enzymes at commencement of 
therapy had LFT done every 2 weeks. Rise of 
more than 3 times the normal was an exclusion 
criterion from the study. Progressive increase in 
LFT, jaundice and reduced appetite were 
considered significant signs of hepatotoxicity even 
when the LFT was not more than 3 times the 
normal. The management of hepatotoxicity was to 
follow the standard protocol of withdrawal of 
drugs, monitoring of LFTs and gradual 
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reintroduction of drugs (Rifampicin first). Other 
drug reactions were also documented but are not 




A total of 70 patients were diagnosed with TB 
from clinic and ward records, but only 62 patients 
aged 3 months to17 years and given ATT over the 
2 year period had complete records that were 
analysed. The mean age (S.D) was 6.9(±4.2) 
years. There were 29 males and 33 females with 
M:F ratio of 1:1.1; 0-4 years were 21 (33.9%), 5-9 
years were 25(40.3%), and those ≥ 10 years were 
16 (25.8%).  Table 1 shows the age, sex and social 
class distribution of the patients seen over the two 
year period. There were 4(6.5%) patients who 
were HIV positive and on anti-retroviral therapy 
(ART); a four and a half year old (1.6%) 
haemoglobin SS patient with rheumatic heart 
disease was also diagnosed with TB; a 7 year old 
known controlled asthmatic also developed TB.  
 
Table 1: Age, Sex and Social Class distribution of patients 
 
Age years                                                                               N(%) 
0-4                                                                                         21(33.9) 
5-9                                                                                         25(40.3) 
≥10                                                                                        16(25.8) 
Total                                                                                      62(100.0) 
Sex  
Male                                                                                     29(46.7) 
Female                                                                                  33(53.3) 
Total                                                                                      62(100.0) 
Social Class 
Low                                                                                      40(64.5) 
Middle                                                                                 16(25.8) 
High                                                                                      6(9.7) 
Total                                                                                    62(100.0) 
 
The diagnosis was Pulmonary TB (PTB) in 
36(58.1%), 11(17.7%) had disseminated TB, 
2(3.2%) patients presented with miliary TB, 
8(12.9%) patients had TB of the spine and 
5(8.1%) were cases of TB adenitis (Table 2). 
Thirty-two (52.6%) had normal nutritional status, 
15(24.1%) were underweight, 12(19.4%) had 
marasmus, while 3(4.8%) had marasmic-
kwashiorkor. A total of 36 patients were under 5 
years of age, and 30 (83.3%) had malnutrition 
with underweight occurring in 15(41.6%). The top 
7 symptoms at presentation were cough, weight 
loss, fever, difficulty in breathing, production of 
sputum, back swelling and haemoptysis (Table 3). 
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Table 3: Symptoms at presentation among cases 
 
Symptom                                                                                         No(%) 
Cough                                                                                               35(56.5) 
Weight loss/failure to thrive                                                        26(41.9) 
Fever                                                                                                 23(37.1) 
Difficulty in breathing                                                                     11(17.7)                                      
Production of sputum                                                                     13(21.0) 
Haemoptysis                                                                                       5(8.1) 
Back swelling                                                                                      7(11.3) 
Neck swelling                                                                                      4(6.5) 
Three patients presented with fast breathing and night sweats; two with generalized lymphadenopathy and 
one with abdominal swelling.  
 
LFT done before ATT was commenced showed 
derangement in liver enzymes in 22 (35.5%), but 
all elevations were below 3 times the upper limit 
of normal (N) from the reference laboratory 
(Table 4).  None of the 22 patients showed 
increasing liver enzymes on further examination at 
2 weeks after the commencement of ATT. At 2 
months after the commencement of treatment, 
LFTs showed AST (0-33 IU/L) and ALT (1-19 
IU/L) ranges below the baseline figures. The range 
of ALT (1-20 IU/L) and AST (5-30 IU/L) at 5 
months is shown in Table 5. 
 
Table 4: Liver function tests at baseline in the study population 
 
 Range  (IU/L)  No. (%) with 




AST (0-15) 6-45  9 (14.5)  53 (85.5)  62  
ALT (0-20) 0-27  13 (21.0)   49(79.0)  62  
ALP  34-698  42 (67.7)  20 (32.3)   
Bilirubin  <20-168       
N.B: Twenty –two (35.5%) of all patients had elevated ALT and or AST 
 
Table 5: Liver function tests at baseline, 2 and 5 months 
 
 AST (0-15 IU/L) 
range  






Baseline  6-45  0-27  34-698  <20-168  
2 month  0-33  1-19  83-385  <20  




The liver is vulnerable to injury from drugs and 
many other toxins because of its unique anatomy 
and physiology. The liver has many functions-
secretory, synthetic, metabolic and detoxifying 
roles. In its metabolic roles, it transforms some 
drugs into toxins that can cause injury to 
hepatocytes. Different mechanisms for 
hepatotoxicity have been studied-cytochrome 
P450-dependent toxicity, bile-induced hepatocyte 
apoptosis, and mitochondrial dysfunction and 
peroxynitrite toxicity. However, it is generally 
thought that many mechanisms play out in ATT 
hepatotoxicity (9). Of utmost importance is the 
occurrence of ATT hepatotoxicity as it can affect 
compliance, outcome of management and result in 
death
 
(10-12). The FDC were recently introduced 
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among children in Nigeria, but there is no clinical 
experience about its use and adverse effects 
related to the liver.  
Tuberculosis as a disease can affect the liver, 
and although no patient in our study presented 
with jaundice, elevated liver enzymes at baseline 
was found in about one-third of the patients. AST, 
ALT singly or in combination were elevated in 
patients before ATT were started although below 
3 times the upper limit as shown in table 4. The 
range of AST and ALT documented in the patients 
at 2 and 5 months of therapy was similar, and 
below the baseline levels. No patient had jaundice 
at presentation or during the course of treatment. 
This is important as jaundice is used as a clinical 
sign for referral of patients on ATT from lower 
level facilities to higher levels of care. The present 
finding supports the fact that drug induced 
hepatotoxicity in children receiving ATT is 
uncommon despite the frequent finding of 
elevated LFT at baseline, and it is consistent with 
the literature which shows that incidence of drug-
induced hepatotoxicity in childhood is between 
3% and 10%; severe hepatotoxicity is documented 
below 1% in children (6-8,10,11). Therefore. with 
the current FDC at the dosages being used in 
Nigeria, the incidence of hepatotoxicity is 
uncommon. This finding is important as it will 
provide a basis on which to counsel patients for 
ATT. In addition, this can allay the anxiety among 
those who care for children with TB.  While this 
may not be enough to make recommendations on 
monitoring hepatotoxicity in children, it will 
provide data for systemic reviews for future 
reference on monitoring.  
The routine monitoring of LFT will increase 
the cost of TB treatment and may not be 
necessary. This is of utmost importance as the 
majority of patients affected are poor as shown by 
the social class of patients in this study. 
Furthermore, an additional test may create 
significant financial barrier to care. However, for 
safety reasons for liver injury may occur in 
children, it could be done when necessary. There 
are calls for early monitoring of LFT in adult 
patients to reduce cases of hepatotoxicity (12,13). 
This cannot be said to be the same for paediatric 
patients.  
Although it is not possible to make 
recommendations on monitoring of children on 
ATT based on this study, for now, it would appear 
safe to individualize care based on presentation 
and baseline LFT. We therefore conclude that 
hepatotoxicity to ATT is uncommon among 
children. This is true even with the use of the FDC 
and in spite of the high incidence of elevated liver 
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